Xetra
30.03.26 | 17:35
2,776 Euro
+0,51 % +0,014
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,774 | 2,800 | 18:29 | |
| 2,774 | 2,800 | 18:26 |
► 30.03.: | | | | | | | | |
► 27.03.: | | | | | | | | 17:00 |
► Aktueller VALNEVA Börsenkurs + Xetra-Orderbuch
► 27.03.: | | | | | | | | 17:00 |
► Aktueller VALNEVA Börsenkurs + Xetra-Orderbuch
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 12,800 | 375 | |||
| 12,500 | 455 | |||
| 9,990 | 1.400 | |||
| 9,900 | 100 | |||
| 5,500 | 2.000 | |||
| 5,100 | 200 | |||
| 2,840 | 632 | |||
| 2,836 | 632 | |||
| 2,832 | 1.106 | |||
| 2,806 | 6.180 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/ayj.htm [/URL] | ||||
| 6.180 | 2,778 | |||
| 1.106 | 2,752 | |||
| 632 | 2,748 | |||
| 632 | 2,744 | |||
| 200 | 2,600 | |||
| 1.000 | 2,280 | |||
| 1.000 | 0,037 | |||
| 1.068 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 11.818 | 1,107 | 13.080 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 16:47:32 | 2,770 | 100 |
| 15:26:23 | 2,852 | 503 |
| 15:22:18 | 2,880 | 2.468 |
| 15:22:18 | 2,880 | 32 |
| 15:22:18 | 2,880 | 300 |
| 10:09:19 | 2,800 | 1.500 |
| 09:04:43 | 2,772 | 1.400 |
| Tagesumsatz Xetra | +0,014 +0,51 % | 14.122 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Sa | Valneva: Überraschende Erkenntnisse, die Anleger jetzt kennen sollten | Hebelschein-Spekulant | |||
| Fr | Weekly Buzz: Corcept Therapeutics Wins FDA Nod In Cancer; Merck & Co. Acquires Terns Pharmaceuticals; Insmed Meets Trial Goals But Valneva Misses | 807 | AFX News | KENILWORTH (NJ) (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S. and Japan, EU withdrawals, mergers, and clinical trial data readouts spanning lung disease... ► Artikel lesen | |
| VALNEVA Aktie jetzt für 0€ handeln | |||||
| Do | Valneva SE - 6-K, Report of foreign issuer | 50 | SEC Filings | ||
| Do | Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC | 63 | GlobeNewswire (USA) | ||
| Mi | VALNEVA SE - Eilmeldung am Abend: Bewegung im Schatten! | 100 | Maximilian Berger |
1 2 3 4 5 Weiter >>
213 Nachrichten in den letzten 12 Monaten
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 13:06 | Connect Biopharma Holdings Limited: Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD | GlobeNewswire (Europe) | - Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease - COPD) patients produced rapid improvement in FEV1 with many patients experiencing... ► Artikel lesen | |
| 16:06 | Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up | PR Newswire | CRO Business Sustained Recovery in Growth, AI-Enabled Drug Discovery Technology Maintained Industry-Leading AdvantagesThroughout 2025, revenue from the Company's CRO business rose from RMB810.9 million... ► Artikel lesen | |
| 14:48 | Immix Biopharma, Inc.: Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones | GlobeNewswire (Europe) | - Full enrollment of BLA-enabling trial complete, per prior guidance -- Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission and planned commercial launch -- Onboarded Chief Medical... ► Artikel lesen | |
| 18:06 | Aelis Farma Reports Its 2025 Annual Financial Results and Confirms Its 2026 Outlook | Business Wire | 2025 has been marked by several significant events: The achievement of key milestones for the Company's two drug candidates:
AEF0117: announcement of the final results of the Phase... ► Artikel lesen | |
| 14:36 | Ultragenyx Pharmaceutical Inc.: Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy | GlobeNewswire (Europe) | NOVATO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VALNEVA SE finden Sie auf Wallstreet Online.